NEHTA

By operation of the Public Governance, Performance and Accountability (Establishing the Australian Digital Health Agency) Rule 2016, on 1 July 2016, all the assets and liabilities of NEHTA will vest in the Australian Digital Health Agency. In this website, on and from 1 July 2016, all references to “National E-Health Transition Authority” or “NEHTA” will be deemed to be references to the Australian Digital Health Agency.

Related News

MEDTECH

AVANTOR® WILL INCREASE GLOBAL PRODUCTION OF SINGLE-USE TECHNOLOGIES TO MEET THE BIOPHARMA DEMAND

Avantor | April 27, 2021

news image

Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies. In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation w...

Read More

INDUSTRIAL IMPACT

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

news image

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More

ANGSTROM BIO LAUNCHES AMPD™, PLATFORM FOR HIGH-ACCURACY, HIGH-FREQUENCY, LOW-COST COVID-19 AND RESPIRATORY PATHOGEN TESTING

Angstrom Bio | October 14, 2020

news image

Angstrom Bio, Inc. today announces the launch of AMPD™, its nanopore sequencing and machine learning powered platform for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. AMPD leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza and to enable schools and places of work to reopen safely and confidently. Angstrom ...

Read More

CELL AND GENE THERAPY

PINNACLE FERTILITY PARTNERS WITH IGENOMIX AS THEIR EXCLUSIVE GENETICS LABORATORY AND GENETIC COUNSELING PROVIDER

Igenomix | June 08, 2022

news image

Pinnacle Fertility (Pinnacle), the fastest-growing network of physician-centered fertility practices representing more than seven clinics and 20 locations nationwide, has partnered with Igenomix as their exclusive preimplantation genetics testing (PGT) laboratory and provider for genetic counseling services. Continuing Pinnacle's commitment to collaborative medical leadership and patient-first care, this strategic partnership was the result of the Medical Council's collective determinati...

Read More
news image

MEDTECH

AVANTOR® WILL INCREASE GLOBAL PRODUCTION OF SINGLE-USE TECHNOLOGIES TO MEET THE BIOPHARMA DEMAND

Avantor | April 27, 2021

Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies. In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation w...

Read More
news image

INDUSTRIAL IMPACT

AMBERSTONE BIOSCIENCES SECURES $12 MILLION SERIES A FINANCING TO ADVANCE IMMUNO-ONCOLOGY PIPELINE OF TUMOR MICROENVIRONMENT ACTIVATED THERAPEUTICS

Amberstone Biosciences, Inc. | January 04, 2022

Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...

Read More
news image

ANGSTROM BIO LAUNCHES AMPD™, PLATFORM FOR HIGH-ACCURACY, HIGH-FREQUENCY, LOW-COST COVID-19 AND RESPIRATORY PATHOGEN TESTING

Angstrom Bio | October 14, 2020

Angstrom Bio, Inc. today announces the launch of AMPD™, its nanopore sequencing and machine learning powered platform for high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing. AMPD leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza and to enable schools and places of work to reopen safely and confidently. Angstrom ...

Read More
news image

CELL AND GENE THERAPY

PINNACLE FERTILITY PARTNERS WITH IGENOMIX AS THEIR EXCLUSIVE GENETICS LABORATORY AND GENETIC COUNSELING PROVIDER

Igenomix | June 08, 2022

Pinnacle Fertility (Pinnacle), the fastest-growing network of physician-centered fertility practices representing more than seven clinics and 20 locations nationwide, has partnered with Igenomix as their exclusive preimplantation genetics testing (PGT) laboratory and provider for genetic counseling services. Continuing Pinnacle's commitment to collaborative medical leadership and patient-first care, this strategic partnership was the result of the Medical Council's collective determinati...

Read More